Telemedicine With Wearable Technologies in Patients Undergoing Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy (TEL-HEMATO Study): Prospective Noninterventional Single-Center Study.
Lidia HurtadoMelinda Gonzalez ConcepcionAida Flix-ValleMarina Ruiz-RomeoSonia Gonzalez-RodriguezMarta PeñaAnnalisa PaviglianitiMaria Angeles Pera JambrinaAnna SuredaCristian OchoaAlberto MussettiPublished in: JMIR formative research (2024)
While the addition of wearable devices to a telehealth clinical platform could have potentially synergic benefits for HCT and CAR T-cell therapy patient monitoring, noncomplete automation of the platform and the absence of a dedicated telemedicine team still represent major limitations to be overcome. This is especially true in our real-life setting where the target population generally comprises patients of older age with a low digital education level.
Keyphrases
- cell therapy
- end stage renal disease
- patients undergoing
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- heart rate
- high throughput
- stem cells
- mesenchymal stem cells
- peritoneal dialysis
- quality improvement
- palliative care
- case report
- cell proliferation
- signaling pathway
- patient reported outcomes
- community dwelling
- cell cycle arrest
- replacement therapy